Wei Guo

Wei Guo

Auto-generated profile, based on publicly available information

Wei Guo

Respiratory Department, Shanxi Cancer Hospital, Taiyuan, People’s Republic of China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SZShen Zhao
Shen Zhao
WZWu Zhuang
Wu Zhuang
BHBaohui Han
Baohui Han
ZSZhengbo Song
Zhengbo Song
WGWei Guo
Wei Guo
WFWenfeng Fang
Wenfeng Fang
EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (anti-EGFR monoclonal antibody) plus osimertinib from preclinical models and an open label, multi-center phase 1b trial (NCT04448379). Primary endpoint of the trial is tolerability. Secondary endpoints include objective response rate, duration of response, disease control rate, progression free survival, overall survival, the pharmacokinetic profile of JMT101, occurrence of anti-drug antibodies and correlation between biomarkers and clinical outcomes. A total of 121 patients are enrolled to receive JMT101 plus osimertinib 160 mg. The most common adverse events are rash (76.9%) and diarrhea (63.6%). The confirmed objective response rate is 36.4%. Median progression-free survival is 8.2 months. Median duration of response is unreached. Subgroup analyses were performed by clinicopathological features and prior treatments. In patients with platinum-refractory diseases (n = 53), confirmed objective response rate is 34.0%, median progression-free survival is 9.2 months and median duration of response is 13.3 months. Responses are observed in distinct 20ins variants and intracranial lesions. Intracranial disease control rate is 87.5%. Confirmed intracranial objective response rate is 25%.

28 February 2025 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
DRDan-Yun Ruan
Dan-Yun Ruan
WHWen-Wen Huang
Wen-Wen Huang
YLYongsheng Li
Yongsheng Li
YZYanqiu Zhao
Yanqiu Zhao
YSYehui Shi
Yehui Shi
HZHongyun Zhao
Hongyun Zhao
HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively targets vascular endothelial growth factor receptor-2, endothelial growth factor receptor, and fibroblast growth factor receptor 1-3. The safety, pharmacokinetics, and efficacy of HA121-28 were assessed in advanced solid tumors (phase 1, ClinicalTrials.gov NCT03994484) and advanced RET fusion-positive non-small-cell lung cancer (RET-TKI naive NSCLC, phase 2, ClinicalTrials.gov NCT05117658). HA121-28 was administered orally in doses range from 25 to 800 mg under the 21-day on/7-day off scheme for a 28-day cycle in phase 1 trial. The recommended dose identified in phase 1 (450 mg) was administered for patients during phase 2. The primary endpoints were the maximum tolerated dose (MTD) in phase 1 and the objective response rate (ORR) in phase 2. 162 patients were enrolled in phase 1 and 48 in phase 2. A total of 600 mg once daily was set as MTD. Across 100–800 mg, the exposure of HA121-28 increased in a dose-dependent manner. Consistent between both trials, diarrhea, rash, and prolonged QTc interval, were the most reported treatment-emergent adverse events. 40.0% (phase 1) and 62.5% (phase 2) patients experienced grade ≥3 treatment-related adverse events, respectively. The overall ORR was 26.8% and the median progression-free survival (PFS) was 5.5 months among 97 NSCLC patients with advanced RET fusion receiving a dose at ≥450 mg once daily. HA121-28 showed encouraging efficacy in advanced RET fusion NSCLC and its toxicity was tolerable in most patients. Nevertheless, cardiotoxicity is a notable concern that warrants careful attention.

1 July 2009 in Oral Oncology Supplement
Verified
Journal Article
Closed access
WGW. Guo
W. Guo
GRGuoxin Ren
Guoxin Ren
WQWeihua Qiu
Weihua Qiu

23 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SZShen Zhao
Shen Zhao
YYYan Yu
Yan Yu
XTXiaoyong Tang
Xiaoyong Tang
JZJianhua Zhan
Jianhua Zhan
XDXiaorong Dong
Xiaorong Dong
WFWenfeng Fang
Wenfeng Fang
Background: EGFR exon 20 insertions (ex20ins) are the third most common EGFR alterations in non-small cell lung cancer (NSCLC). Currently approved targeted therapy for EGFR ex20ins-positive NSCLC has either inadequate efficacy in far-loop ex20ins or unfavourable toxicities such as thromboembolism. We evaluated becotatug plus osimertinib, a dual EGFR blockade strategy with complementary effects on signalling inhibition and receptor downregulation, in patients with EGFR ex20ins-positive NSCLC.Methods: This phase 2 trial enrolled patients with platinum-pretreated EGFR ex20ins-positive NSCLC at 21 sites in China. Patients received becotatug 6mg/kg intravenously every 2 weeks plus osimertinib 160mg orally once daily. Primary endpoint was independent review committee (IRC)-assessed confirmed objective response rate (ORR) in the intention-to-treat (ITT) population. Registered at ClinicalTrials.gov (NCT05132777).Findings: Between Nov 26, 2021 and Jun 21, 2023, 126 patients were enrolled. 112 patients had centrally confirmed EGFR ex20ins and comprised the ITT population. IRC-assessed confirmed ORR was 50·0% (95% CI 40·4–59·6). Disease control rate was 79·5%. Median progression-free survival was 6·9 months (95% CI 5·9–8·8). Median overall survival was 18·0 months (95% CI 13·4–22·5). Efficacy was consistent across helical (ORR=77·8%), near-loop (ORR=46·9%) and far-loop (ORR=48·7%) insertions. Common grade≥3 treatment-related adverse events were rash (31·7%), dry skin (11·9%) and oral mucositis (11·1%). Interstitial lung disease (2·4%) and infusion-related reactions (1·6%) were uncommon.Interpretation: Becotatug plus osimertinib demonstrated meaningful activity in platinum-pretreated EGFR ex20ins-positive NSCLC, with manageable safety and consistent efficacy across insertion locations. Dual EGFR blockade represents a promising strategy for these patients, especially in those with far-loop ex20ins.Funding: Shanghai JMT-Bio Technology Co., Ltd, AstraZeneca, Guangzhou Burning Rock Dx Co., Ltd.

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HZHuaqiang Zhou
Huaqiang Zhou
QZQing Zhou
Qing Zhou
QGQisen Guo
Qisen Guo
WGWei Guo
Wei Guo
GCGongyan Chen
Gongyan Chen
LZLi Zhang
Li Zhang
Purpose: The ongoing OCEAN II study (ClinicalTrials.gov identifier: NCT05195632) evaluates encorafenib in combination with binimetinib (E+B) in Chinese participants with BRAFV600E-mutated metastatic non-small cell lung cancer (NSCLC).Methods: Participants with unresectable stage IV BRAFV600E-mutated NSCLC (treatment-naïve or with prior systemic therapy excluding BRAF/MEK-inhibitors), were enrolled in a phase 2 study with two parts: safety lead-in (SLI) and pivotal part (PP). Participants received daily oral encorafenib (450mg) and twice daily oral binimetinib (90mg total). Primary endpoints were dose-limiting toxicities (DLT) during SLI and confirmed objective response rate by independent central review (cORR-ICR) during PP. Secondary endpoints were other measures of efficacy, safety, and pharmacokinetics.Results: In total, 63 participants were enrolled. One DLT (non-serious Grade 3 lipase increased) during SLI considered possibly related to E+B resolved without intervention, supporting initiation of PP. Pre-defined statistical efficacy criteria on the first 50 participants were met. In the main analysis, cORR-ICR was 59% (95%CI 45–72). At a later ad hoc analysis, cORR-ICR was 61% (95%CI 47–74), disease control rate 87% (95%CI 75–95). Medians (95%CI) were, time-to-response 1.8 months, duration of response 17.5 months, progression-free survival 13.8 months (7.5–not estimable), overall survival 27.9 months (14.7–30.0). 98.4% of participants experienced ≥1 treatment-related TEAE, and 55.6% had any Grade ≥3 TEAE. Nine (14.3%) participants discontinued any drug due to adverse events.Conclusion: These data confirm the clinical benefit of E+B in Chinese participants with BRAFV600E-mNSCLC, a population with distinct genomic and disease characteristics. No new safety concerns were identified in Chinese participants.

1 March 2026 in Journal of Thoracic Disease
Verified
Journal Article
Open access
JLJunge Liu
Junge Liu
HLHaodong Lu
Haodong Lu
XZXinyao Zheng
Xinyao Zheng
FSFangfang Shen
Fangfang Shen
WGWei Guo
Wei Guo
Both neoadjuvant and perioperative immunotherapies have emerged as standard-of-care treatments for patients with resectable non-small cell lung cancer (NSCLC). However, the optimal treatment strategy regarding the necessity of the adjuvant phase remains undefined due to a lack of direct head-to-head comparisons. This study thus aimed to quantitatively evaluate whether extending immunotherapy into the adjuvant phase confers a survival benefit over neoadjuvant therapy alone in patients with stage III NSCLC. A systematic search of the PubMed, Embase, Cochrane Library, and Web of Science databases was conducted for randomized controlled trials (RCTs) published as of June 21, 2025. Individual patient data (IPD) were reconstructed from Kaplan-Meier (KM) curves of the eligible studies. The primary end points were event-free survival (EFS) and overall survival (OS). Statistical analyses included stratified log-rank tests, Cox proportional hazards regression, and restricted mean survival time (RMST) analysis. Seven studies (six RCTs and one single-arm phase II trial) involving 1,436 patients with stage III NSCLC were included in the analysis. In the overall population, neoadjuvant and perioperative immunotherapies demonstrated comparable efficacy, with no significant difference in EFS [hazard ratio (HR) =0.99; 95% confidence interval (CI): 0.72–1.36; P=0.94]. Subgroup analysis indicated stage-dependent outcomes: EFS was similar in the stage IIIA cohort (HR =1.04; P=0.87), whereas a nonsignificant advantage for neoadjuvant therapy was observed in the mixed-stage IIIA–IIIB cohort (HR =0.52; 95% CI: 0.27–1.03; P=0.05). In the analysis of OS, which was restricted to the stage IIIA population due to data maturity, no significant difference was found between the two strategies (HR =0.97; 95% CI: 0.58–1.64; P=0.92). The 5-year RMST of OS was 48.51 months for the neoadjuvant group and 47.56 months for the perioperative group (difference =0.95 months; P=0.69). The findings from this IPD-based quantitative analysis suggest that neoadjuvant immunotherapy may yield EFS and OS outcomes comparable to those of perioperative immunotherapy in patients with resectable stage III NSCLC. However, given the indirect nature of the comparison, these results should be considered hypothesis-generating; they provide a rationale for investigating a neoadjuvant-only strategy as a potential de-escalation approach. Future head-to-head trials are warranted to validate these findings, particularly among patients with stage IIIB disease.